PedAM
Pediatric Disease Annotations & Medicines
| arthritis | ||||
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:19) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs1061622 | 15252214 | 7133 | TNFRSF1B | umls:C0003864 | BeFree | To assess the association between the tumour necrosis factor receptor 2 (TNFR2) 196 M/R single-nucleotide polymorphism and rheumatoid arthritis (RA) severity by taking advantage of the extremes of phenotype that exist in arthritis. | 0.008544182 | 2004 | TNFRSF1B | 1 | 12192898 | T | G |
| rs1143679 | 20666624 | 3684 | ITGAM | umls:C0003864 | BeFree | ITGAM Arg77His is associated with disease susceptibility, arthritis, and renal symptoms in systemic lupus erythematosus patients from a sample of the Polish population. | 0.003724241 | 2011 | ITGAM | 16 | 31265490 | G | A |
| rs12046117 | 19116933 | 79679 | VTCN1 | umls:C0003864 | GWASCAT | Identification of a novel susceptibility locus for juvenile idiopathic arthritis by genome-wide association analysis. | 0.12 | 2009 | VTCN1 | 1 | 117208743 | C | T |
| rs12150220 | 22235789 | 22861 | NLRP1 | umls:C0003864 | BeFree | Our results demonstrated that NLRP1 rs2670660 SNP and the NLRP1 rs12150220-rs2670660 A-G haplotype were associated with SLE in our study population, and in particular with the development of nephritis, rash and arthritis. | 0.000271442 | 2012 | NLRP1 | 17 | 5582047 | A | T |
| rs12411988 | 22354554 | 221035 | REEP3 | umls:C0003864 | GWASCAT | Genome-wide association analysis of juvenile idiopathic arthritis identifies a new susceptibility locus at chromosomal region 3q13. | 0.12 | 2012 | REEP3 | 10 | 63555637 | G | C |
| rs1800562 | 17904763 | 3077 | HFE | umls:C0003864 | BeFree | Hereditary hemochromatosis (HH) is a genetic disease associated with iron overload, in which individuals homozygous for the mutant C282Y HFE associated allele are at risk of developing liver disease, diabetes and arthritis. | 0.013192369 | 2008 | HFE | 6 | 26092913 | G | A |
| rs1893592 | 25843625 | 53347 | UBASH3A | umls:C0003864 | BeFree | A statistically significant association was observed between UBASH3A rs1893592 C allele and skin rash, oral ulcer and arthritis (p<0.05). | 0.000271442 | 2015 | UBASH3A | 21 | 42434957 | A | C |
| rs20541 | 21613309 | 3596 | IL13 | umls:C0003864 | BeFree | The authors genotyped three groups of Caucasians: those with PsA, those with psoriasis without arthritis (PsC) and healthy controls for the rs20541 and rs848 IL13 single nucleotide polymorphisms (SNPs). | 0.000271442 | 2011 | IL13 | 5 | 132660272 | A | G |
| rs2230926 | 19774492 | 7128 | TNFAIP3 | umls:C0003864 | BeFree | Interestingly, rs2230926 of TNFAIP3 was also associated with arthritis, ANA and some other subphenotypes of the disease. | 0.003452799 | 2010 | TNFAIP3 | 6 | 137874929 | T | C,G |
| rs2395148 | 18576341 | 10665 | C6orf10 | umls:C0003864 | GWASCAT | Association of the TRAF1-C5 locus on chromosome 9 with juvenile idiopathic arthritis. | 0.12 | 2008 | C6orf10;LOC101929163 | 6 | 32353777 | G | T |
| rs2476601 | 17436241 | 26191 | PTPN22 | umls:C0003864 | BeFree | The aim of this study was to use and compare three different definitions of interaction between the two major genetic risk factors of RA--the HLA-DRB1 shared epitope (SE) alleles and the PTPN22 R620W allele--in three large case-control studies: the Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study, the North American RA Consortium (NARAC) study, and the Dutch Leiden Early Arthritis Clinic study (in total, 1,977 cases and 2,405 controls). | 0.0089015 | 2007 | PTPN22;AP4B1-AS1 | 1 | 113834946 | A | G |
| rs2476601 | 17436241 | 3123 | HLA-DRB1 | umls:C0003864 | BeFree | The aim of this study was to use and compare three different definitions of interaction between the two major genetic risk factors of RA--the HLA-DRB1 shared epitope (SE) alleles and the PTPN22 R620W allele--in three large case-control studies: the Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study, the North American RA Consortium (NARAC) study, and the Dutch Leiden Early Arthritis Clinic study (in total, 1,977 cases and 2,405 controls). | 0.058922883 | 2007 | PTPN22;AP4B1-AS1 | 1 | 113834946 | A | G |
| rs2670660 | 22235789 | 22861 | NLRP1 | umls:C0003864 | BeFree | Our results demonstrated that NLRP1 rs2670660 SNP and the NLRP1 rs12150220-rs2670660 A-G haplotype were associated with SLE in our study population, and in particular with the development of nephritis, rash and arthritis. | 0.000271442 | 2012 | NA | 17 | 5615686 | A | G |
| rs4688011 | 22354554 | 51300 | TIMMDC1 | umls:C0003864 | GWASCAT | Genome-wide association analysis of juvenile idiopathic arthritis identifies a new susceptibility locus at chromosomal region 3q13. | 0.12 | 2012 | TIMMDC1 | 3 | 119508400 | G | A,C |
| rs4986791 | 24243911 | 7099 | TLR4 | umls:C0003864 | BeFree | In the Polish population of SLE patients, 1196C/T polymorphism of TLR4 gene does not increase the risk of development of NPSLE; however, genotype CC and a dominant allele C is associated with arthritis in the course of SLE. | 0.006720033 | 2014 | TLR4 | 9 | 117713324 | C | T |
| rs5743708 | 18975326 | 7097 | TLR2 | umls:C0003864 | BeFree | In contrast, compared with normal controls, one of the rare TLR-2 SNPs (rs5743708, R753Q) was associated with the development of arthritis and extraarticular features (P = 0.015 by chi-square test). | 0.003810118 | 2008 | TLR2 | 4 | 153705165 | G | A |
| rs6479891 | 22354554 | 221037 | JMJD1C | umls:C0003864 | GWASCAT | Genome-wide association analysis of juvenile idiopathic arthritis identifies a new susceptibility locus at chromosomal region 3q13. | 0.12 | 2012 | JMJD1C | 10 | 63246696 | T | C |
| rs7574865 | 22937072 | 6775 | STAT4 | umls:C0003864 | BeFree | The TT genotype of the STAT4 rs7574865 polymorphism is associated with high disease activity and disability in patients with early arthritis. | 0.002909916 | 2012 | STAT4 | 2 | 191099907 | T | G |
| rs848 | 21613309 | 3596 | IL13 | umls:C0003864 | BeFree | The authors genotyped three groups of Caucasians: those with PsA, those with psoriasis without arthritis (PsC) and healthy controls for the rs20541 and rs848 IL13 single nucleotide polymorphisms (SNPs). | 0.000271442 | 2011 | IL13 | 5 | 132660808 | A | C |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:18) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0003864 | cabergoline | C047047 | 81409-90-7 | arthritis | MESH:D001168 | marker/mechanism | 18172015 | ||
| C0003864 | carbamazepine | D002220 | 298-46-4 | arthritis | MESH:D001168 | marker/mechanism | 6462508 | ||
| C0003864 | carbimazole | D002231 | 22232-54-8 | arthritis | MESH:D001168 | marker/mechanism | 15785249 | ||
| C0003864 | cefotaxime | D002439 | 63527-52-6 | arthritis | MESH:D001168 | marker/mechanism | 2041948 | ||
| C0003864 | celecoxib | D000068579 | - | arthritis | MESH:D001168 | therapeutic | 15297470 | ||
| C0003864 | chloroquine | D002738 | 1954/5/7 | arthritis | MESH:D001168 | therapeutic | 12954536 | ||
| C0003864 | diclofenac | D004008 | 15307-86-5 | arthritis | MESH:D001168 | therapeutic | 24152722 | ||
| C0003864 | indomethacin | D007213 | 53-86-1 | arthritis | MESH:D001168 | therapeutic | 6881008 | ||
| C0003864 | meloxicam | C065757 | 71125-38-7 | arthritis | MESH:D001168 | therapeutic | 24152722 | ||
| C0003864 | methotrexate | D008727 | 1959/5/2 | arthritis | MESH:D001168 | therapeutic | 18173932 | ||
| C0003864 | nicotine | D009538 | - | arthritis | MESH:D001168 | marker/mechanism | 8746358 | ||
| C0003864 | propylthiouracil | D011441 | 51-52-5 | arthritis | MESH:D001168 | marker/mechanism | 10088956 | ||
| C0003864 | pyrazinamide | D011718 | 98-96-4 | arthritis | MESH:D001168 | marker/mechanism | 2915734 | ||
| C0003864 | rifampin | D012293 | 13292-46-1 | arthritis | MESH:D001168 | marker/mechanism | 2915734 | ||
| C0003864 | rosiglitazone | C089730 | - | arthritis | MESH:D001168 | therapeutic | 20211202 | ||
| C0003864 | sulindac | D013467 | 38194-50-2 | arthritis | MESH:D001168 | therapeutic | 6291491 | ||
| C0003864 | tolmetin | D014046 | 26171-23-3 | arthritis | MESH:D001168 | therapeutic | 3684403 | ||
| C0003864 | tretinoin | D014212 | 302-79-4 | arthritis | MESH:D001168 | marker/mechanism | 10741706 | ||
FDA approved drug and dosage information(Total Drugs:4) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D001168 | mobic | meloxicam | 7.5MG | TABLET;ORAL | Prescription | AB | Yes | No |
| MESH:D001168 | mobic | meloxicam | 7.5MG/5ML | SUSPENSION;ORAL | Prescription | None | Yes | Yes |
| MESH:D001168 | celebrex | celecoxib | 100MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
| MESH:D001168 | celebrex | celecoxib | 100MG | CAPSULE;ORAL | Prescription | None | No | No |
FDA labeling changes(Total Drugs:4) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D001168 | 11/8/2005 | mobic | meloxicam | Relief of signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis | Safety and efficacy established in patients 2 years of age and older Clinical studies evaluated doses ranging from 0.125 mg/kg/day to 0.375 mg/kg/day. There was no additional benefit demonstrated by doses above 0.125 mg/kg/day in the clinical trials. The lowest effective dose should be used Adverse events in children were similar to those in adults including skin reactions and gastrointestinal bleed risk Information on dose, PK parameters, AE profile and clinical studies | Labeling | - | - | B, P | - | Boehringer Ingelheim | 04/15/2005 | FALSE' |
| MESH:D001168 | 11/8/2005 | mobic | meloxicam | Relief of signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis | Safety and efficacy established in patients 2 years of age and older Clinical studies evaluated doses ranging from 0.125 mg/kg/day to 0.375 mg/kg/day. There was no additional benefit demonstrated by doses above 0.125 mg/kg/day in the clinical trials. The lowest effective dose should be used Adverse events in children were similar to those in adults including skin reactions and gastrointestinal bleed risk Information on dose, PK parameters, AE profile and clinical studies | Labeling | - | - | B, P | - | Boehringer Ingelheim | 04/15/2005 | FALSE' |
| MESH:D001168 | 12/15/2006 | celebrex | celecoxib | Relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA) | New indication in 2 years and older Has not been studied in patients < 2 years, in patients with body weight < 10 kg, or in patients with active systemic features Celecoxib should be used only with caution in patients with systemic onset JRA due to the risk for serious adverse reactions including the risk of disseminated intravascular coagulation The long-term cardiovascular toxicity in children has not been evaluated; it is unknown if the long-term risk may be similar to that seen in adults New 50 mg capsule developed Information on adding contents of a capsule to applesauce. for patients with difficulty swallowing capsules Information on dose, clinical studies, PK parameters, AEs | Labeling | B | - | - | - | Pfizer | 08/23/2006 | FALSE' |
| MESH:D001168 | 12/15/2006 | celebrex | celecoxib | Relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA) | New indication in 2 years and older Has not been studied in patients < 2 years, in patients with body weight < 10 kg, or in patients with active systemic features Celecoxib should be used only with caution in patients with systemic onset JRA due to the risk for serious adverse reactions including the risk of disseminated intravascular coagulation The long-term cardiovascular toxicity in children has not been evaluated; it is unknown if the long-term risk may be similar to that seen in adults New 50 mg capsule developed Information on adding contents of a capsule to applesauce. for patients with difficulty swallowing capsules Information on dose, clinical studies, PK parameters, AEs | Labeling | B | - | - | - | Pfizer | 08/23/2006 | FALSE' |